Year All2024202320222021 KemPharm Reports Second Quarter 2022 Financial Results and Corporate Updates 08-11-2022 KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications 08-09-2022 KemPharm to Report Second Quarter 2022 Financial Results 08-04-2022 KemPharm to Present at the Canaccord Genuity 42nd Annual Growth Conference 08-02-2022 KemPharm to Participate in the 2022 Joint NNPDF-INPDA Conference and Meeting 07-26-2022 KemPharm Announces Research Affirming Serdexmethylphenidate’s Lower Potential for Abuse Featured in Peer-Reviewed Publication, Current Medical Research & Opinion 06-01-2022 KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline 05-15-2022 KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates 05-12-2022 KemPharm to Present at Multiple Upcoming Investor Conferences 05-11-2022 KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH) 05-05-2022
KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications 08-09-2022
KemPharm Announces Research Affirming Serdexmethylphenidate’s Lower Potential for Abuse Featured in Peer-Reviewed Publication, Current Medical Research & Opinion 06-01-2022
KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline 05-15-2022
KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH) 05-05-2022
